DxMedical Cloud™
Technology for overwhelmingly high-speed detection from all over the world.
We use our unique algorithm to deliver the latest technology and product information from around the world in real time.
Explore the future of healthcare with carefully selected information.
Explore the future of healthcare with carefully selected information.
Login
How We Help You To Empower Your Business
POINT 1.
Quickly Deliver Technical Information
We deliver what you seek quickly and in a short time from technical information from all over the world
POINT 2.
Briefly to the Point
A wealth of detailed features makes it easy to understand the main points
POINT 3.
Help with Growth Strategies
The report is also packed with analytical information from the perspective of growth and long-term strategies for business use
Catch Up on the Latest Information
from Around the World
from Around the World
In today's world, where the world is networked by advances in information technology and numerous technologies are evolving at an astonishing speed, it is extremely difficult to manually collect and manage the vast amount of information from all over the world.
DxMedical Cloud™ collects and analyzes professional information from around the world and uses proprietary algorithms to quickly and accurately deliver the information you seek and the best information for you.
search
Quick search in Japanese
You can quickly search for information published in various languages around the world in Japanese. Get the information you need from the vast amount of information available worldwide without having to worry about language barriers.
emergency
Recommendations for You
DxMedical Cloud's proprietary algorithms predict the best information based on your interests and preferences and deliver it to you daily. Stay one step ahead of the curve without the hassle of searching, maximizing your daily information gathering.
Fuzzy Search
In addition to word matching, the search by similar and related keywords delivers news that is often missed due to paraphrasing and shaky spelling.
Japanese Localization
By providing titles and summaries of information from around the world in Japanese, it streamlines the process of “finding” the information you want from search results.
Academic Search
For researchers and professionals, you can search and browse more specialized information, such as articles submitted to journals by universities and research institutes.
More features to enhance your team's productivity
Bookmark
Instantly save and manage information that you like or want to look at later because you don't have time, with the bookmark function. You can access the information you need without hassle, saving you a great deal of time and effort.
Note Editor
Simple and intuitive operation allows you to quickly consolidate all information into a notebook and organize information efficiently. It can be used as a powerful tool for effective information sharing.
Information sharing
A wide range of information sharing tools are available, including chat and note sharing functions. We support information sharing with your team in all situations, from casual information sharing to organizing information in teams.
Collaboration
Provides task management functions specifically designed to make information gathering and sharing more efficient. In addition to regular task management functions, this useful tool supports information gathering and sharing, improving the productivity of the entire team.
DigitalMedical Open Innovation
BrainEnergy produce DigitalMedical open
innovation from Tokyo, where you can experience the intersection of cool and passionate design and
technology.
Transform Your Business With Cloud
Looking for the Future of Health Care
OUR TECHNOLOGY HELPS YOUR BUSINESS
Our technology will help your business
Technology
Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies
Vivos Therapeutics and SoundHealth announced a collaboration to expand access to SoundHealth's innovative FDA-cleared allergy and sleep technologies. Through Vivos' extensive network of dentists and sleep healthcare providers, products like the Sonu® Band for nasal congestion and the Spatial Sleep™ band for promoting deep sleep will be distributed. These devices utilize AI and vibro-acoustic neuromodulation to address underlying causes of breathing-related sleep disorders, including sleep apnea.
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI
NVIDIA and Eli Lilly announced a first-of-its-kind AI co-innovation lab to tackle pharmaceutical industry challenges. The companies will jointly invest up to $1 billion over five years in the San Francisco Bay Area lab, which brings together world-leading scientists, AI researchers, and engineers. The lab infrastructure will be built on NVIDIA BioNeMo platform and NVIDIA Vera Rubin architecture to address the hardest problems in drug discovery.
Aesyra SA Completes Clinical Investigation for Dental and Sleep Disorders
Aesyra SA, a Swiss medtech company, successfully completed a clinical investigation of AesyBite Active, an intelligent oral appliance for treating and preventing sleep bruxism through biofeedback. The study demonstrated a statistically significant 60.6% reduction in sleep bruxism activity, along with a positive safety and usability profile. Unlike conventional passive splints, AesyBite Active offers a differentiated approach by combining a customized oral appliance with embedded sensors and active biofeedback for real-time detection and reduction of bruxism without disturbing sleep.
LumiMind Brings Real-Time Brain Signal Control and Sleep Neurotech to CES 2026
At CES 2026, LumiMind unveiled LumiSleep, a non-invasive consumer sleep device based on real-time EEG monitoring. The device uses integrated EEG sensors in a soft headband to detect the brain's "Sleep Onset Pattern™" and gently modulates neural activity with personalized acoustic output. LumiMind also demonstrated its non-invasive Brain-Computer Interface (BCI) platform controlling complex digital environments (e.g., gaming), showcasing its high performance. The company aims to shift BCI technology from invasive medical applications to practical, wearable solutions for everyday use.
Vertex and CRISPR Set Ambitious 2026 Revenue Goal for Gene Therapy Casgevy
Vertex Pharmaceuticals and CRISPR Therapeutics announced an ambitious revenue target for their gene therapy, Casgevy, expecting sales to nearly triple in 2026, reaching $500 million combined with their new pain medication Journavx. After an initially slow uptake following its approval for sickle cell disease and beta thalassemia, patient access is expanding, with approximately 90% of U.S. patients now covered by insurance. Casgevy is also available in 10 other countries, and Vertex is filing to expand its label to include 5 to 11-year-olds, supported by positive Phase 3 data in this younger cohort. Both companies express strong confidence in Casgevy's future growth trajectory.
CoreFX evolves into science-backed nutraceutical ingredient supplier
CoreFX Ingredients LLC, originally a specialty ingredients company focused on dairy and lipid systems, has evolved into a science-driven technology partner dedicated to improving the stability and bioavailability of nutrients and bioactive compounds. This transformation is driven by industry demand for credible in-body functionality and increased investment in scientific R&D. With two innovation centers, including a new facility housing the CoreNhanced technical optimization platform, CoreFX delivers taste-neutral, clean-label powdered nutrients in their most bioavailable and stable forms. The recent acquisition of Disruption Labs' IP further strengthens expertise in emulsification, encapsulation, and micro-structuring, accelerating product development in food, beverage, nutraceutical, and specialized health applications.
German Start-Up Secures Billion-Dollar Deal with Pharma Giant
Dresden-based Seamless Therapeutics has signed a strategic agreement with Eli Lilly and Company, valued at up to $1.12 billion, focusing on treating hearing impairment. Seamless specializes in high-precision DNA recombinases to correct genetic flaws causing hearing loss. The CEO stated this collaboration confirms their gene-editing platform's potential for treating various illnesses, aiming to improve outcomes for patients with genetically caused hearing loss. Eli Lilly has also significantly invested in expanding its German operations. This highlights Germany's appeal as a location for international startups and investors in the pharmaceutical sector.
No More Tests, Bracelet-Like Device Aims to Track Women’s Hormones Real-Time
Clair, co-founded by an Indian-origin Stanford graduate, has developed a non-invasive, wrist-worn device that tracks women's hormones in real-time. This device utilizes biosensors and machine learning models to estimate levels of five critical hormones (estrogen, progesterone, LH, FSH, and PdG), aiming to eliminate the need for invasive blood or urine tests. Expected to ease fertility treatments and advance women's health research, the device is currently seeking US FDA approval, with independent trials planned at the Stanford Gladstone Initiative.
2nd Nature Launches First AI-Discovered Portfolio of Functional Ingredients
2nd Nature, developer of the AgWaste Portal AI platform, has launched its first portfolio of AI-discovered functional ingredients, including non-calorie natural sweeteners and non-sodium umami enhancers. These ingredients, found in the side streams of widely processed crops like wheat, soy, rice, peanut, and corn, are designed to help manufacturers reformulate food and beverage products to reduce sugar and sodium while maintaining taste and functionality. The company has filed a patent for these newly identified compounds, which are expected to be available for commercial sampling in Q2 2026.
Abbott Launches "Liberta RC™ DBS System," a Compact Rechargeable Deep Brain Stimulation System with Remote Programming Capabilities
Abbott Medical Japan has launched the "Liberta RC™ DBS System," a rechargeable deep brain stimulation (DBS) system designed to alleviate essential tremor, Parkinson's disease motor symptoms, and dystonia. Approximately 23% smaller than previous models, it incorporates Abbott's proprietary remote programming feature, "NeuroSphere™ Virtual Clinic." This allows patients to receive program adjustments from home, reducing hospital visits, and requires only about 10 recharges annually, enhancing treatment convenience and quality of life. The system aims to provide new treatment options for patients in remote areas who may have difficulty accessing DBS therapy.
Researchers from NHK and Chiba University develop an OLED device that can emit light and generate solar energy at the same time
NHK Science & Technology Research Laboratories (STRL), in collaboration with Professor Hirohiko Fukagawa from Chiba University, has developed an OLED display device that can emit light while simultaneously harvest solar energy. NHK says that this is the first time that such a device has been developed, where it is capable of blue light emission.
Sibel Health Awarded a $500,000 Drug Development Tools Research Grant by the FDA for a Novel AI-Enabled Wearable Sensor for Scratch Monitoring
Sibel Health, a leader in wearable biosensing and digital health, today announced that it has been awarded a competitive grant from the U.S. Food and Drug Administration (FDA) to advance towards full qualification of a novel clinical outcome assessment for scratching behaviors in atopic dermatitis (AD) as a drug development tool.
The award supports the next phase of development for Sibel's ADAM™ sensor — a hand-mounted wearable device that objectively measures scratching during both sleep and daytime activities combined with an AI-enabled algorithm.
Hydrocolloids Boost Orally Disintegrating Film Performance
In a groundbreaking study set to redefine the landscape of oral drug delivery systems, researchers have unveiled new insights into the physicochemical and sensory properties of orally disintegrating films (ODFs), specifically focusing on the role of hydrocolloids. This pioneering research, recently published in Food Science and Biotechnology, promises to revolutionize how pharmaceutical and nutraceutical compounds are administered, offering profound implications for patient compliance and therapeutic efficacy.
Orally disintegrating films have garnered considerable attention over the past decade due to their rapid dissolution upon contact with saliva, bypassing the need for water and enhancing convenience, especially among pediatric and geriatric populations. However, the challenge remains to optimize these films’ texture, dissolution rate, and overall sensory acceptance without compromising structural integrity. The team led by Park, Ganbat, and Han tackled these challenges head-on by systematically evaluating diverse hydrocolloid matrices within ODF formulations.